RevoluGen is the rebranded name of Moorlodge Biotech Ventures Ltd. (MBV) a company founded in 1998, by serial entrepreneur Dr Minter who had also founded Tepnel Life Sciences in 1990. In 1992 shares in Tepnel life Sciences were made available on the London Stock Exchange and Tepnel Life Sciences was sold to GenProbe Corporation in 2010 for $155 million.
RevoluGen now develops molecular laboratory tools invented by Dr. Georgios Patsos. These tools are primarily used for the extraction and purification of High Molecular Weight DNA (HMW-DNA) from cells. The lead Fire Monkey and Fire Flower tools are particularly good at extracting HMW-DNA that contains sufficient long DNA fragments to markedly improve long-read genomic sequencing.
New management was brought in during early 2016 led by Pieter Mulier (CEO) who then brought in the experience of Dr. Erling Refsum, Dr. Ann Simon and Simon Davenport QC. The Moorlodge Biotech Ventures name was changed to RevoluGen Ltd at end 2016 and a fundamental restructuring of the company was guided by Simmons & Simmons in mid 2017 with audited accounts provided by Grant Thornton. The HDL licensee was acquired for shares in August 2018 in order to simplify the corporate structure and complete the reorganisation.
RevoluGen now has filed patents on the basic Fire Monkey NAIP chemistry and the Fire Flower size selection technology. RevoluGen will now focus on commercialisation of these products.
Pieter has 24 years of experience in listed and non-listed equities in Central Europe, United States and the CIS and an outstanding track record of investment banking within the biotech sector. During the mid-1990s he was with Nomura International in London, a dominant securities house with a substantial in-house trading book. He headed up the Sales Desk of the Healthcare and Technology Group, which was one of the most profitable in-house groups of Nomura at the time. Having gained extensive experience of complex corporate finance transactions, it was a natural progression for him to set up Mulier Capital in 2002. To date he has transacted deals with an aggregate value of over 3 billion US$. He has an in-depth knowledge of transactions in all asset classes and has managed / syndicated these transactions from sourcing to closing. He holds the rank of reserve Lt-Col in the Netherlands cavalry, Huzaren van Boreel.
Adam was instrumental in the initial funding of the company and continues to oversee its financial and investor related matters.
Over the last 25 years, Adam has grown his practice into a thriving Group of businesses that acts for High Net Worth individuals and SMEs. Over the last 10 years in particular, Adam has assisted several SMEs in their formative stages by providing fund raising capability, structuring expertise and advice on taxation and exit planning.
Erling Refsum trained in medicine at Guys Hospital and then worked in the NHS for 9 years becoming a Fellow of the Royal College of Surgeons of Edinburgh in 1983. He subsequently joined the Nomura Research Institute in 1987 and became the head of the Lifesciences Equities Research Team being voted the number one biotechnology and healthcare analyst by the Reuters UK smaller company survey for 3 years running between 1999 and 2001. Whilst at Nomura, he won the first Hungarian Privatisation Round for Gideon Richter, was key to gaining 25 biotech corporate clients and generated over a 100% return on a £50m Biotech Bottom Fishing Book. Since leaving Nomura in late 2005 he has predominantly worked at finding finance for small biotech companies at Mulier Capital and Eden Corporate Finance, raising over $60m for clients.
Georgios completed his postgraduate studies in Virology/Immunology and was awarded an MSc from Manchester University, and a PhD from Bristol University. He continued his research examining the effect of glycosylation inhibitor molecules on cancer cell growth at Bristol University. He then moved to Heidelberg University on a Marie-Curie fellowship where he focused on the application of plant proteins as glycodiagnostic tools for cancer, producing several publications in this area. He then furthered his post-doctoral experience in more market orientated projects. Firstly, at Liege University were he worked on the in silico identification of cancer vaccine targets on behalf of GlaxoSmithKline Biologicals Ltd. Secondly, at the National University of Ireland, Galway, working on the development of glycan specific molecular diagnostic tools. During his post-doctoral posts he became an expert in cancer glycoscience and glycodiagnostics. His diagnostic work and diverse experience were the ideal stepping stones into the biotech sector, where Georgios is an inventor for RevoluGen’s technologies.
Stephen has a demonstrable track record of invention and innovation in the biotechnology sector and he has filed circa 70 patents over the last 30 years. He founded Tepnel Diagnostics Ltd in 1982 with Terry Colley and in 1992 shares in Tepnel Diagnostics were made available on the London Stock Exchange with an initial market capitalisation of over £80m. Tepnel Life Sciences was later sold to GenProbe Corporation in 2010 for $155 million. In 2006 Stephen was invited to take on the role of Chief Technical Officer and Director of the National Nanotechnology Centre for Food and Pharmaceuticals a wholly owned subsidiary of Nottingham University. In that capacity he invented and patented a new form of crystalline salt that was designed to allow a reduction of salt levels in foods by up to 30% without reducing the flavour or shelf life of the foodstuff. This technology can be widely used in foods allowing companies to meet the European guide lines on food standards.
Dr. Ann Simon has worked in finance, particularly in the life sciences and technology sectors, since 1985. She is a non-executive director of AIM-listed Scientific Digital Imaging, Spectrum (General Partner) and Lumacron and also provides consultancy in the areas of finance, strategic planning, enablement and funding. Over the past 15 years she has held executive roles as CFO of a number of companies including Pyreos, mLED, Sphere Medical and Genosis, Prior to that she undertook corporate finance advisory work at Cazenove & Co for over a decade for clients ranging from start-ups to FTSE100 companies. She has managed IPOs (London full list and AIM), corporate acquisitions and trade sales and fund raisings in the public and private markets. She was on the FSA’s Financial Information Theme Team 2002-3. Ann has a PhD in physics and completed 10 years of postgraduate work mainly at the Cavendish Laboratory, Cambridge with periods spent in Germany, France and the USA.
Alex was educated at Bradfield College as a Moulsdale Scholar, the London School of Economics and the University of British Columbia. Starting his career in the International Capital Markets at Tokai Bank, then a top ten bank by balance sheet, he was Head of Middle East Distribution for fixed income and traded the AUD/CDN/NZD books.
In 1998 his investment management consultancy firm was merged into LAI International, a NASDAQ listed enterprise. Later he was approached to effect a turn-round, becoming co-managing partner of RKA. It blossomed into an EIU award winning professional services business, encompassing corporate advisory, human capital and market leading competitive intelligence offerings to some of the world’s largest financial services firms, including Goldman Sachs, Deutsche Bank and Dresdner Kleinwort Benson.
Martin St Quinton (60) was born in Yorkshire. He graduated from Durham University in 1979 and went on to obtain his MBA in the USA.
In 1980 he started The Saint Group a private office equipment company which was sold to Danka plc in 1993. From then until 1999 he was CEO of Danka’s International Operations. During this six-year period he acquired over 50 companies in 30 different countries. Danka grew to be the world’s second largest photocopier company with sales in excess of £1bn.
In 2000, he founded another company Azzurri Communications, a UK based Voice & Data Integrator, which grew to 700 staff and £150m turnover in 6 years. In 2006 Azzurri was sold for £180m to The Prudential Group. In recognition of his achievements at Azzurri Martin was named Ernst & Young Entrepreneur of the Year in 2003.
In a 30 year career he has acquired over 70 companies and integrated these businesses to create two groups of companies both of which were subsequently sold.
Martin is currently a Non Executive Director of 6 other companies including Gloucester Rugby Club where he is Chairman. He lives in Hampshire with his wife and 4 children.
Legal counsel advisor. Leading silk, Legal 500 in Civil Fraud, Insolvency and Commercial Litigation